Press Release BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway Jul 6
Press Release BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF Jun 15